Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 May 29:10:1144.
doi: 10.3389/fimmu.2019.01144. eCollection 2019.

Bacterial Protein Toll-Like-Receptor Agonists: A Novel Perspective on Vaccine Adjuvants

Affiliations
Review

Bacterial Protein Toll-Like-Receptor Agonists: A Novel Perspective on Vaccine Adjuvants

Sudeep Kumar et al. Front Immunol. .

Abstract

Adjuvants have been used in vaccines for over a century, however, the search for safe and effective vaccine adjuvants continues. In recent decades toll-like-receptor (TLR) agonists have been investigated as potential vaccine adjuvants. In this regard, the majority of the currently investigated TLR agonists are non-protein microbial components such as lipopolysaccharides, oligonucleotides, and lipopeptides. On the other hand, a growing number of studies reveal that TLR signaling and immune responses can be activated by numerous bacterial proteins. However, their potential roles as adjuvants have been somewhat overlooked. Herein, we discuss several such bacterial proteins which exhibit adjuvant properties, including the activation of TLR signaling, antigen presenting cell maturation, pro-inflammatory cytokine production and adaptive immune response. The protein nature of these TLR agonists presents several unique features not shared by non-protein TLR agonists. These properties include the amenability for modifying the structure and function as necessary for optimal immunogenicity and minimal toxicity. Protein adjuvants can be genetically fused to protein antigens which ensure the co-delivery of adjuvant-antigen not only into the same cell but also in the same endocytic cargo, leading to more effective activation of innate and adaptive immune response.

Keywords: TLR; TLR agonist; adjuvant; antigen presenting cells; cell-mediated immunity; vaccine.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mechanism of action of adjuvants. Following administration adjuvants induce a local (A) pro-inflammatory niche which is characterized by (B) influx of leukocytes, (C) pro-inflammatory cytokines, (D) activation of APCs, and (E) migration of APCs to draining lymph nodes.
Figure 2
Figure 2
Immunological consequences of interaction between antigen-TLR agonist fusion protein and antigen presenting cells. (A) Antigens physically linked to TLR agonists are endocytosed along with the related receptor, the TLR dependent signaling in endosomes results in rapid maturation of phagosome, antigen processing, MHCII invariant chain processing, loading of processed antigens to MHCII and display of MHCII-peptide. (B) TLR signaling initiated by binding of antigen-TLR agonist results in maturation of APCs and surface expression of co-stimulatory molecules (CD80/86). (C) TLR signaling elicits cytokine secretion. (D) The APCs displaying co-stimulatory markers and MHCII-peptide activate naïve T cells. (E) The synergistic effects of A, B C and D cumulate in the generation of polarized T cells (Th1, Th2, or Th17) depending on the kind of cytokine secreted by APCs in response to respective TLR ligands.

Similar articles

Cited by

References

    1. Ozawa S, Clark S, Portnoy A, Grewal S, Stack ML, Sinha A, et al. . Estimated economic impact of vaccinations in 73 low- and middle-income countries, 2001-2020. Bull World Health Organ. (2017) 95:629–38. 10.2471/BLT.16.178475 - DOI - PMC - PubMed
    1. Morabia A. Edward Jenner's 1798 report of challenge experiments demonstrating the protective effects of cowpox against smallpox. J R Soc Med. (2018) 111:255–7. 10.1177/0141076818783658 - DOI - PMC - PubMed
    1. Greenwood B. The contribution of vaccination to global health: past, present and future. Philos Transac R Soc London Series B Biol Sci. (2014) 369:20130433. 10.1098/rstb.2013.0433 - DOI - PMC - PubMed
    1. Delany I, Rappuoli R, De Gregorio E. Vaccines for the 21st century. EMBO Mol Med. (2014) 6:708–20. 10.1002/emmm.201403876 - DOI - PMC - PubMed
    1. Perrie Y, Mohammed AR, Kirby DJ, McNeil SE, Bramwell VW. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int J Pharmaceut. (2008) 364:272–80. 10.1016/j.ijpharm.2008.04.036 - DOI - PubMed

MeSH terms